{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-24-000206","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2024-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.372549+00:00","generated_at":"2026-05-30T16:11:10.874602+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neurocrine appoints Kyle Gano as CEO effective Oct 11, 2024; base salary $900k","bullets":["Kyle Gano, Ph.D. named President and CEO effective October 11, 2024, under an amended employment agreement.","Annual base salary of $900,000; target cash bonus of 100% of base salary.","Promotion equity grants: $750k stock options, $300k RSUs, $450k PRSUs (total $1.5M).","Severance includes 1.5x salary plus bonus for non-CIC termination; 2x for CIC termination with full vesting."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-24-000206","json":"https://secwatch.observer/filing/0000914475-24-000206.json","markdown":"https://secwatch.observer/filing/0000914475-24-000206.md","text":"https://secwatch.observer/filing/0000914475-24-000206.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000206/0000914475-24-000206-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000206/nbix-20241011.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T16:11:10.874602+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2496aa104d","claim":"Kyle Gano was appointed as President and Chief Executive Officer at NEUROCRINE BIOSCIENCES INC.","evidence_excerpt":"Pursuant to the Employment Agreement, Dr. Gano will serve as Neurocrine Biosciences’ President and Chief Executive Officer effective October 11, 2024 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000206/0000914475-24-000206-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}